Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers

Rie Shimada; Kiyoaki Tsukahara; Soichiro Takase; Isaku Okamoto; Hiroki Sato; Yasuaki Katsube; Ryo Maruyama; Akira Shimizu

doi:10.1177/1179670717749231

Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers

Jpn Clin Med. 2018 Jan 29:9:1179670717749231. doi: 10.1177/1179670717749231. eCollection 2018.

Authors

Rie Shimada¹, Kiyoaki Tsukahara¹, Soichiro Takase¹, Isaku Okamoto¹, Hiroki Sato¹, Yasuaki Katsube¹, Ryo Maruyama¹, Akira Shimizu¹

Affiliation

¹ Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.

Abstract

The use of generic drugs has been increasing. However, studies of the safety of generic cisplatin (CDDP) for the treatment of head and neck cancer (HNC) have not been reported. This study investigated the treatment completion rates and incidence of CDDP-related adverse events in patients with advanced HNC treated with concurrent chemoradiotherapy (CRT) using generic CDDP. This study included 72 patients who received concurrent CRT using generic CDDP. The number of courses of CDDP was 3 in 45 patients, 2 in 19 patients, and 1 in 8 patients. During 154 courses of 80 mg/m² generic CDDP, grade 3/4 leukopenia in 21 (14%), neutropenia in 18 (12%), and hypochromia in 8 (5%) cases were reported. Grade 2 elevated serum creatinine occurred in 4 cases (3%), but no grade 3/4 elevated serum creatinine was reported. These results suggest that CRT using generic CDDP is well tolerated in patients with HNC.

Keywords: Generic cisplatin formulations; chemoradiotherapy; chemotherapy; head and neck cancer.